Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Melanocortin Receptor 4 (MC4R) Pipeline Review, H2 2016 Featuring AstraZeneca, Mallinckrodt, Obexia, Palatin Technologies, Pfizer & Retrophin - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016" report to their offering.

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 7 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Melanocortin Receptor 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Melanocortin Receptor 4 - Overview
  5. Pipeline Products for Melanocortin Receptor 4 - Comparative Analysis
  6. Melanocortin Receptor 4 - Therapeutics under Development by Companies
  7. Melanocortin Receptor 4 - Therapeutics under Investigation by Universities/Institutes
  8. Melanocortin Receptor 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Melanocortin Receptor 4 - Products under Development by Companies
  13. Melanocortin Receptor 4 - Products under Investigation by Universities/Institutes
  14. Melanocortin Receptor 4 - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Retrophin Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.